Research output: Contribution to journal › Article › peer-review
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. / Oxford Immunology Network Covid-19 Response T cell Consortium.
In: Nature immunology, Vol. 21, No. 11, 11.2020, p. 1336–1345.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
AU - Oxford Immunology Network Covid-19 Response T cell Consortium
AU - Peng, Yanchun
AU - Mentzer, Alexander J
AU - Liu, Guihai
AU - Yao, Xuan
AU - Yin, Zixi
AU - Dong, Danning
AU - Dejnirattisai, Wanwisa
AU - Rostron, Timothy
AU - Supasa, Piyada
AU - Liu, Chang
AU - López-Camacho, César
AU - Slon-Campos, Jose
AU - Zhao, Yuguang
AU - Stuart, David I
AU - Paesen, Guido C
AU - Grimes, Jonathan M
AU - Antson, Alfred A
AU - Bayfield, Oliver W
AU - Hawkins, Dorothy E D P
AU - Ker, De-Sheng
AU - Wang, Beibei
AU - Turtle, Lance
AU - Subramaniam, Krishanthi
AU - Thomson, Paul
AU - Zhang, Ping
AU - Dold, Christina
AU - Ratcliff, Jeremy
AU - Simmonds, Peter
AU - de Silva, Thushan
AU - Sopp, Paul
AU - Wellington, Dannielle
AU - Rajapaksa, Ushani
AU - Chen, Yi-Ling
AU - Salio, Mariolina
AU - Napolitani, Giorgio
AU - Paes, Wayne
AU - Borrow, Persephone
AU - Kessler, Benedikt M
AU - Fry, Jeremy W
AU - Schwabe, Nikolai F
AU - Semple, Malcolm G
AU - Baillie, J Kenneth
AU - Moore, Shona C
AU - Openshaw, Peter J M
AU - Ansari, M Azim
AU - Dunachie, Susanna
AU - Barnes, Eleanor
AU - Frater, John
AU - Kerr, Georgina
AU - Goulder, Philip
N1 - © The Author(s), under exclusive licence to Springer Nature America, Inc. 2020. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.
PY - 2020/11
Y1 - 2020/11
N2 - The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors, using interferon-γ-based assays with peptides spanning SARS-CoV-2 except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe as compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific antibody responses. We identified 41 peptides containing CD4+ and/or CD8+ epitopes, including six immunodominant regions. Six optimized CD8+ epitopes were defined, with peptide-MHC pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific CD8+ T cells were observed. The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.
AB - The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors, using interferon-γ-based assays with peptides spanning SARS-CoV-2 except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe as compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific antibody responses. We identified 41 peptides containing CD4+ and/or CD8+ epitopes, including six immunodominant regions. Six optimized CD8+ epitopes were defined, with peptide-MHC pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific CD8+ T cells were observed. The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.
U2 - 10.1038/s41590-020-0782-6
DO - 10.1038/s41590-020-0782-6
M3 - Article
C2 - 32887977
VL - 21
SP - 1336
EP - 1345
JO - Nature immunology
JF - Nature immunology
SN - 1529-2908
IS - 11
ER -